Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have identified TNF-α inhibitors reported to be useful for the treatment of autoimmune diseases.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, cardiometabolic syndrome, cardiovascular disorders, Parkinson’s disease and Alzheimer’s disease.

Hangzhou Polymed Biopharmaceuticals Inc. has disclosed proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently bonded to an EGFR del19/Thr790Met/Cys797Ser triple mutant and/or EGFR Leu858Arg/Thr790Met/Cys797Ser triple mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.

Shanghai Huilun Pharmaceutical Co. Ltd. has described compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression.

Nxera Pharma UK Ltd. has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; CDHF12; PTC), tyrosine-protein kinase receptor UFO (AXL) and vascular endothelial growth factor receptor 2 (VEGFR2; FLK1) inhibitors reported to be useful for the treatment of cancer.

Remegen Ltd. has synthesized antibody-drug conjugates consisting of anti-CDCP1 antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.

Kangbaida (Sichuan) Biotechnology Co. Ltd. has disclosed pyroptosis and NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, gout, inflammatory disorders, multiple sclerosis, psoriasis, autoimmune diseases and Alzheimer’s disease.

Scientists at Healzen Therapeutics Co. Ltd. and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have described GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Dana-Farber Cancer Institute Inc. has divulged tumor necrosis factor receptor superfamily member 1A (TNFRSF1A; TNFR1; p55; CD120a) antagonists reported to be useful for the treatment of inflammation and neuroinflammation.